Abstract
Accumulating evidence suggests that most solid malignancies consist of heterogeneous tumor cells and that a relatively small subpopulation, which shares biological features with stem cells, survives through potentially lethal stresses such as chemotherapy and radiation treatment. Since the survival of this subpopulation of cancer stem cells (CSC) plays a critical role in recurrence, it must be eradicated in order to cure cancer. We previously reported that vaccination with CD133+ murine melanoma cells exhibiting biological CSC features induced CSC-specific effector T cells. These were capable of eradicating CD133+ tumor cells in vivo, thereby curing the parental tumor. In the current study, we indicated that DEAD/H (Asp–Glu–Ala–Asp/His) box polypeptide 3, X-linked (DDX3X) is an immunogenic protein preferentially expressed in CD133+ tumor cells. Vaccination with DDX3X primed specific T cells, resulting in protective and therapeutic antitumor immunity. The DDX3X-primed CD4+ T cells produced CD133+ tumor-specific IFNγ and IL-17 and mediated potent antitumor therapeutic efficacy. DDX3X is expressed in various human cancer cells, including lung, colon, and breast cancer cells. These results suggest that anti-DDX3X immunotherapy is a promising treatment option in efforts to eradicate CSC in the clinical setting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li Y, Laterra J (2012) Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 72:576–580. doi:10.1158/0008-5472.CAN-11-3070
Sharma SV, Lee DY, Li B et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69–80. doi:10.1016/j.cell.2010.02.027
Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017. doi:10.1634/stemcells.2008-0601
Milas L, Raju U, Liao Z, Ajani J (2005) Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32:S78–S81. doi:10.1053/j.seminoncol.2005.04.028
Diehn M, Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98:1755–1757. doi:10.1093/jnci/djj505
Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333. doi:10.1158/0008-5472.CAN-04-3327
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.1038/nature05236
Malanchi I, Peinado H, Kassen D et al (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452:650–653
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115. doi:10.1038/nature05384
Kagamu H, Shu S (1998) Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 160:3444–3452
Fujita N, Kagamu H, Yoshizawa H et al (2001) CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 167:5678–5688
Miyabayashi T, Kagamu H, Koshio J et al. (2011) Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother. doi:10.1007/s00262-011-1063-x
Lahn BT, Page DC (1997) Functional coherence of the human Y chromosome. Science 278:675–680
Pugh TJ, Weeraratne SD, Archer TC et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488:106–110. doi:10.1038/nature11329
Stransky N, Egloff AM, Tward AD et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–1160. doi:10.1126/science.1208130
Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:2497–2506. doi:10.1056/NEJMoa1109016
Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F, Yoshizawa H (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175:5058–5066
Watanabe S, Kagamu H, Yoshizawa H, Fujita N, Tanaka H, Tanaka J, Gejyo F (2003) The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 171:5828–5836
Botlagunta M, Vesuna F, Mironchik Y et al (2008) Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 27:3912–3922. doi:10.1038/onc.2008.33
Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H (2011) Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res 17:1895–1905. doi:10.1158/1078-0432.CCR-10-2316
Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH (2006) DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res 66:6579–6588. doi:10.1158/0008-5472.CAN-05-2415
Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715. doi:10.1016/j.cell.2008.03.027
Sun M, Song L, Zhou T, Gillespie GY, Jope RS (2011) The Role of DDX3 in regulating snail. Biochim Biophys Acta. doi:10.1016/j.bbamcr.2011.01.003
Fan X, Eberhart CG (2008) Medulloblastoma stem cells. J Clin Oncol 26:2821–2827. doi:10.1200/JCO.2007.15.2264
Rosinski KV, Fujii N, Mito JK et al (2008) DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111:4817–4826. doi:10.1182/blood-2007-06-096313
Porcheray F, Miklos DB, Floyd BH et al (2011) Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation 92:359–365. doi:10.1097/TP.0b013e3182244cc3
Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J (2004) Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 199:1133–1142. doi:10.1084/jem.20031560
Miklos DB, Kim HT, Zorn E et al (2004) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103:353–359
Vogt MH, van den Muijsenberg JW, Goulmy E et al (2002) The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 99:3027–3032
Acknowledgments
This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan. Hiroshi Kagamu received research fund from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan).
Conflict of interest
All other authors have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Jun Koshio and Hiroshi Kagamu have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Koshio, J., Kagamu, H., Nozaki, K. et al. DEAD/H (Asp–Glu–Ala–Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells. Cancer Immunol Immunother 62, 1619–1628 (2013). https://doi.org/10.1007/s00262-013-1467-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-013-1467-x